The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy

Table 1

Distribution of demographic data, pathological features collected from pretherapy core biopsies and parameters investigated in the posttherapy specimens.

	Count (%)
Laterality
Rt	69 (45.1%)
Lt	84 (54.9%)
Histological type
IDC+	123 (80.4%)
Non-IDC	30 (19.6%)
Histological type details
IDC	123 (80.4%)
ILC	11 (7.2%)
Medullary	9 (5.9%)
Metaplastic	5 (3.3%)
Tubulolobular	2 (1.3%)
Grade
I	6 (3.9%)
II	86 (56.2%)
III	61 (39.9%)
LVI+
Yes	89 (58.2%)
No	64 (41.8%)
M. subtype+
Luminal	76 (49.7%)
TNBC	77 (50.3%)
Lymphocyte groups
Lymphocyte poor	27 (17.6%)
Lymphocyte intermediate	66 (43.1%)
Lymphocyte predominant	60 (39.2%)
Post-neoadjuvant T stage+
T0	36 (23.5%)
T1	60 (39.2%)
T2	51 (33.3%)
T3	5 (3.3%)
T4	1 (0.7%)
N stage+
N0	66 (43.1%)
N1	34 (22.2%)
N2	31 (20.3%)
N3	22 (14.4%)
Postneoadjuvant RCB
RCB 0	29 (19.0%)
RCB I	5 (3.3%)
RCB II	50 (32.7%)
RCB III	69 (45.1%)
Postneoadjuvant pCR groups
PCR group	29 (19.0%)
Non-PCR group	124 (81.0%)

+IDC: invasive duct carcinoma; +ILC: invasive lobular carcinoma; +LVI: lymphovascular invasion; M. subtype: molecular subtype; N stage: nodal stage; +pCR: pathological complete response; RCB: residual cancer burden; T stage: tumor stage; +TNBC: triple negative breast cancer.